Vaccines

The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.

CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.

Steven Damon, Micron Biomedical CEO, discusses the promising future of Micron’s microneedle technology, which allows for painless vaccine delivery through pressing a small patch onto the skin.

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Taking a broad view of big pharma share price movements as the sector reported 2024 financials, company-specific issues were complicated by geopolitical factors including Donald Trump’s tariff announcements.

AstraZeneca CEO Pascal Soriot said it was “fake news” to describe the UK as the worst place in the western world for pharma companies to invest and blamed the decision to pull plans for a new £450m vaccines facility near Liverpool on it simply not being economically viable without more government support.

A combination of heightened competition, destocking at vaccination clinics and a slowing economy resulted in a disappointing year for major Chinese vaccine companies.

As rival Bavarian Nordic closes in on US approval for its chikungunya vaccine for people aged 12 and older, the French biotech has presented positive data for its already-approved jab Ixchiq in adolescents and children.